CG Oncology Q3 2026 Results: Net Loss of $56.9M, Loss Widens
CG Oncology reported a net loss of $196.1 million for the first nine months of 2026, driven by a significant increase in research and development expenses to $137.6 million. The company strengthened its balance sheet through a follow-on public offering that raised $391.6 million, ending the period with over $984 million in cash and marketable securities.
- Key figure
- Net loss $56.9M